A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Project - Authors - KSSG Research Database

Project

A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Scheduled · 2024 until 2029

Ehl Niklas, Vetsch Susanne

Ehl, Niklas

resident physician
Kardiologie · Dept. I

Vetsch, Susanne

Kardiologie · Dept. I